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ABSTRACT 
Objective: A novel LC-ESI-MS/MS method was developed and validated for simultaneous determination of atorvastatin calcium (ATR) and 
olmesartan medoxomil (OLM) in rat plasma and evaluated pharmacokinetic study in rats.  
Methods: The analytes were separated on aquasil C18 
Results: The limit of detections (LODs) and the limit of quantifications (LOQs) were 0.15ng/mL and 1.0ng/mL for ATR and 0.21ng/mL and 
1.0ng/mL for OLM respectively. The determined intra- and inter-day precisions were less than 10% and the accuracy was within 90 - 110 %. The 
stability and extraction recoveries of the analytes were in the acceptable range.  
reversed phase column and the detection of target compounds was done in Multiple Reaction 
Monitoring (MRM) mode using an ion trap mass spectrometer. The method was validated according to the ICH guidelines.  
Conclusion: This method was successfully applied to the pharmacokinetic study of ATR and OLM in rats.  
Keywords: Atorvastatin calcium, Olmesartan medoxomil, Electron spray Ionization, Multiple Reaction Monitoring, Pharmacokinetic study. 
 
INTRODUCTION 
Control of hypertension and hyperlipidaemia are important for the 
prevention of cardio vascular risk factors. The combination of 
atorvastatin calcium (ATR) along with olmesartan medoxamil (OLM) 
is used in the treatment of coexisting hypertension and 
hyperlipidemia in adult patients. Atorvastatin calcium (ATR) is 
chemically described as calcium salt of (β R, 8 R)-2-(4 – fluoro-
phenyl) – α, δ di hydroxyl 5(1 methyl ethyl) 1, 3, phenyl, 4 (phenyl 
amino) carbonyl) -1 H pyrroleheptanoic acid tri hydrate used as 
antihyperlipidaemic [1]. ATR is liver selective competitive inhibitor 
of 3-hydroxy-3-methylglutaryl Co enzyme A (HMG Co A) reductase, 
the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl 
Co enzyme A to mevalonate, a precursor of cholesterol biosynthesis. 
It also lowers elevated total and LDL cholesterol, apolipoprotein-B, 
and triglyceride levels in patients with primary 
hypercholesterolemia and mixed dislipidemia [2,3]. ATR is rapidly 
absorbed after oral administration due to presystemic clearance in 
gastro intesinal mucosa and metabolism in liver. Its absolute 
bioavalability is approximatly 12% and low plasma concentration is 
achieved following administration of the drug [4]. 
Olmesartan is administered as an ester prodrug, olmesartan 
medoxomil (CS-866) which is hydrolyzed to active olmesartan 
during absorption from gastrointestinal tract that acts as an 
angiotensin II receptor blocker effective in lowering blood pressure 
in hypertensive patients [5-7]. Chemically it is known as 2,3-
dihydroxy-2-butenyl4-[1-hydroxy-1-methylethy]-2-propyl-1-[p(o-
1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-
carbonate [8]. The peak plasma concentration (C max
Several analytical methods including LC-UV and LC-MS have been 
reported for bioavailability of ATR [10-20] and OLM [21-26] either 
individually or in combination with other drugs. However, so far, no 
single and precise analytical method was reported for the 
simultaneous estimation of ATR and OLM in rat plasma. Hence it is 
important to determine the bioavailability of ATR and OLM when 
these two drugs were administered in combination. Therefore, the 
aim of this study was to develop a new, simple, rapid, precise and 
economic method for the simultaneous determination of these two 
drugs in rat plasma using liquid chromatography electrospray 
ionization tandem mass spectrometry. The developed bio analytical 
method has been validated according to the ICH guidelines [27] and 
applied successfully for pharmacokinetic study in rats.  
) of olmesartan 
is reached after one to two hours after oral administration. The 
bioavailability of olmesartan is not affected by food. Olmesartan is 
eliminated in a biphasic manner, with a terminal elimination half-life 
of approximately 13 hours. It is highly bound to plasma proteins 
(99%) and does not penetrate red blood cells [9]. 
MATERIALS AND METHODS 
Apparatus and Chemicals 
The reference standards of Olmesartan medoxomil (OLM) was gift 
sample from Ranbaxy Laboratories Ltd. (Gurgaon, India). 
Atorvastatin calcium (ATV) and Losartan (LOS) were obtained from 
Aurobindo Pharma Ltd. (Hyderabad, India). Their structures and 
purities were confirmed by HPLC, nuclear magnetic resonance and 
high resolution mass spectrometric methods. All the chemicals were 
showed purity more than 99 %. High purity deionized water was 
obtained using a Direct Q ultra-pure water system from Millipore 
(Milford, MA, USA). HPLC grade acetonitrile and methanol were 
purchased from E-Merck (Mumbai, India). Analytical grade formic 
acid and glacial acetic acid were purchased from SD-Fine Chemicals 
Ltd. (Mumbai, India). 0.45µM Syringe filters with nylon membrane 
was obtained from Pall scientific, (Bangloor, KA, USA). Spinix Vortex 
shaker was obtained from Jaibro Scientific Works (New Delhi, India). 
Biofuge refrigerated centrifuge was purchased from Her-aeus 
(Germany). The animals were procured from National Institute of 
Nutrition, Tarnaka, Hyderabad. 
Standard solutions and fortification  
Standard solutions of ATV, OLM and LOS were prepared at 1mg/mL 
concentration by dissolving 10 mg of each drug in 10 mL of 
acetonitrile and water (50:50, v/v). They were further diluted with 
acetonitrile to obtain working standard solutions for spiking 
purposes. Calibration standard and quality control samples in 
plasma were prepared by fortifying the corresponding working 
standard solutions with drug-free rat plasma. A volume of 10 µL of 
each working standard solution was spiked to 100 µL of blank 
plasma samples to produce final concentrations equivalent to 1, 2, 5, 
10, 20, 50, 100, 200, 500 and 1000ng/mL. A volume of 10 µL 
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internal standard losartan was added to each concentration to 
produce a final concentration of 20ng/mL. The QC samples were 
prepared in the same way as calibration samples to yield low, medium 
and high concentration levels of 1, 5, 50 and 500 ng/mL for ATV and 
OLM respectively. Linearity of the two drugs was evaluated using least 
square linear regression analysis and regression equations were used for 
determination of concentrations via back calculations. 
Extraction procedure 
Analytes were extracted from plasma by employing protein 
precipitation method. A volume of 200 µL of chilled acetonitrile (-20 
°C) was added as a protein precipitating agent, vortexed for 1 min 
and then centrifuged at 10,000 rpm for 10 min on Biofuge 
refrigerated centrifuge at 4o
A Thermo Finnegan LCQ Advantage Max ion trap mass spectrometer 
coupled to a Thermo Finnegan HPLC system containing surveyor LC 
quaternary pump plus, surveyor auto-sampler plus (Thermo 
Scientific, San Jose, CA, USA). The Xcalibur software (version 2.1) 
was used for data acquisition and analysis.  
C. The supernatant layer was separated 
and filtered through 0.45 µm syringe filters and 20 µL of the sample 
solution was injected for LC-MS/MS analysis.  
LC-ESI-MS/MS analysis 
The separation of the analytes was carried out on an Aquasil-C18 (50 
mm length 2.1 mm internal diameter and 5 µm particle size) column 
protected with Phenomenex security guard column C18
Mass Spectral determination was done in electrospray ionization 
positive ion mode on an ion trap mass spectrometer. The full scan 
MS and MS/MS spectra of each analyte were obtained by direct 
infusion of the respected sample solution at a concentration of 
10µg/mL solution prepared in the mobile phase.  
 (4 mm×2 
mm ID) (Phenomenex, India) and was operated at ambient 
temperature. The mobile phase composed with acetonitrile (pump-
A) and water containing 0.04 % glacial acetic acid (pump-B) used in 
(80:20, v/v) isocratic mode at an optimum flow rate of 0.25 mL/min 
for 3 min. 
The flow rates of sheath gas and auxiliary gas were optimized and 
set to 30 psi and 5 psi respectively. The needle spray voltage was set 
to 4.5 kV. Helium was used as damping and collision gas tuned for 
each analyte to obtain good signal intensity in MS2
The structures and ESI-MS/MS spectra of analytes were presented in 
Fig. 1. The quantitative analysis of drugs was done in multiple 
reactions monitoring (MRM) mode. The precursor ions, product 
ions, and LC-ESI-MS/MS parameters were depicted in Table 1. 
 experiment.  
  
Table 1: LC-ESI-MRM parameters of all the analytes 
Analyte Retention time ESI mode MRM transition Collision Energy 
losartan 1.20 ± 0.3 positive 423 → 405 30 
atorvastatin 1.68 ± 0.3 positive 559 → 440 44 
olmesartan 1.83 ± 0.3 positive 559 → 541 30 
 
 
Fig. 1: LC–ESI-MS/MS spectra of A) losartan, B) olmesartan and 
C) atorvastatin and their corresponding structures 
 
Method validation 
The bio analytical method was validated according to the FDA 
guidelines (US Food and Drug Administration, May 2001). The 
method was validated in terms of selectivity, specificity, linearity, 
limit of detection (LOD), limit of quantification (LOQ), accuracy, 
precision, recovery, and matrix effect. 
The selectivity and specificity were assessed by comparing the 
chromatograms of six different sources of blank rat plasma with 
those of the corresponding spiked plasma. Each blank plasma 
sample was tested using the proposed extraction procedure and LC–
MS/MS conditions to ensure no interference of ATV, OLM and the ISs 
from blank plasma. LODs of the drugs were determined based on 
signal intensity three times more than baseline noise (S/N=3) and 
LOQs of the drugs were determined based on intensity of signal 
which was ten times more than the noise (S/N=10). 
The linearity of the assay was evaluated by constructing calibration 
curves with different concentrations ranging from 1 to 1000ng/mL 
for atorvastatin and olmesartan. The calibration curves were 
constructed by plotting the each respective peak area ratios of ATV 
and OLM to the LOS (IS) against the concentrations of ATV and OLM 
respectively, using the weighting factor of 1/x2
Quality Control (QC) samples were prepared in blank plasma at the 
concentrations of 1 (LLOQ), 5, 50 (MLOQs) and 500ng/mL (HLOQ) 
for ATV and OLM in six replicates (n=6) for assessing the accuracy, 
intra- and inter-batch precisions (reproducibility) of the method. All 
QC samples were prepared freshly on three consecutive days and 
analyzed in each analytical batch along with the unknown samples. 
.  
Extraction recoveries for drugs were determined by post extraction 
and pre extraction spiking at four concentration levels 1, 5, 50 and 
500ng/mL. In post extraction, 100 µL blank plasma samples were 
extracted with 200 µL of acetonitrile, drugs mixture solutions were 
spiked into the blank extracts along with the IS at 10µg/mL. In pre 
extraction, similar concentration levels were spiked in to 100 µL 
blank plasma samples prior to extraction. The samples were 
prepared and analyzed in six replicates. The extraction recovery 
values and validation results of two drugs were showed in Table 2. 
The matrix effect (ME) of the method was measured by extracting 
100 µL of blank plasma samples. The residues after evaporation 
were reconstituted with 200 µL of standard solution containing the 
drugs at four concentration levels 1, 5, 50 and 500ng/mL along with 
the internal standard 20ng/mL. The percentage ME was calculated 
by comparing the relative area ratios (analyte/IS) obtained from the 
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matrix and standards prepared in neat solvent at similar 
concentration levels 1, 5, 50 and 500ng/mL. The ME (%) observed in 
the range of ± 15 to 23 in rat plasma.  The stabilities of ATV and OLM 
in plasma at different storage condition were evaluated and the 
results were expressed as mean percentage accuracies. The short 
term stability was determined by keeping QC samples in six 
replicates (n=6) at room temperature for 24 h. The auto sampler 
stability was evaluated by keeping the QC samples at 4oC for 24 h in 
auto sampler before analysis. Freeze-thaw stability of QC samples 
were analyzed after three freeze- thaw cycles by freezing at -80o
  
C for 
24 h and thawing at room temperature for 24 h. The stability studies 
of analytes were showed in Table 3. 
Table 2: The validation parameters of drugs at six replicates (n=6). 
Analyte Concentration 
ng/mL 
Intra day Inter day  
Extraction recovery 
 
RSD (%) Accuracy (%) RSD (%) Accuracy (%) RSD (%) 
ATV 1 90.55 2.05 91.42 3.97 72.12 10.65 
5 94.60 5.50 90.71 1.99 83.64 6.29 
50 98.65 6.50 102.55 3.19 91.83 8.32 
500 98.48 3.18 99.31 2.70 95.28 6.75 
OLM 1 90.69 3.22 93.01 5.10 74.39 9.43 
5 91.58 4.77 90.40 2.86 76.28 6.48 
50 97.75 5.73 104.17 4.21 84.39 10.53 
500 104.37 5.58 100.96 4.33 94.96 8.93 
 
Table 3: Stability studies of ATV and OLM in rat plasma at four QC levels in six replicates (n=6). 
Storage conditions ATV OLM 
Mean accuracy (%), RSD (%) Mean accuracy (%), RSD (%) 
1 5 50 500 1 5 50 500 
Short term stability  

















Freeze/thaw stability  

















Pre-preparative stability  



















Six healthy Wistar rats with an average weight of 200 ± 10 g were 
procured from National Institute of Nutrition, Tarnaka, Hyderabad 
(India). The animals were housed in BIOSAFE, under standard (22 ± 
2 °C, 60–70% humidity) laboratory conditions, maintained on a 12-h 
natural day–night cycle, with free access to standard food and water. 
Animals were acclimatized to laboratory conditions before the 
study. The experimental protocol was approved by the Institutional 
Animal Ethical Committee (IAEC) of IICT, Hyderabad (India) 
(CPCSEA registration number: 97/1999/CPCSEA, Dated 28.4.1999) 
and was conducted according to the CPCSEA guidelines on the use 
and care of experimental animals. After overnight fasting of animals, 
ATV and OLM mixture was prepared and administered orally to the 
rats as a gum acacia suspension at a dose of 1 mg/kg and 2 mg/kg 
respectively. A volume of 0.3 mL of blood was collected in EDTA 
coated glass tubes at time intervals of 0.083, 0.25, 0.5, 1, 1.5, 2, 3, 4, 
6, 8, 12 and 24h after drug administration. Blood was centrifuged at 
5000 rpm for 10 min and the plasma was separated and stored at -
80 o
 
C until analysis. A volume of 20 µL was injected into the LC-
MS/MS system. Pharmacokinetic parameters were estimated using 
non-compartmental analysis with WinNonlin (version 1.1) kinetic 
software. The pharmacokinetic parameters were of drugs were 
presented in Table 4. 
Table 4: Pharmacokinetic parameters of atorvastatin and olmesartan in rat plasma (n = 6) after oral administration (mean ± SD). 
Parameter ATV OLM 
Cmax 391.72 ± 36.14  (ng/mL) 762.02 ± 33.50 
Tmax 0.90 ± 0.22  (h) 0.70 ± 0.27 
AUC0-t 864.37± 115.32 (ng mL/h) 1778.82 ± 339.04 
AUC0-∞ 873.97 ± 118.15 (ng mL/h) 1794.30 ± 348.26 
t1/2 3.89 ± 0.40 (h) 3.56 ± 0.45 
Cmax is the peak plasma concentration, Tmax is the time to reach peak plasma concentration, t1/2 is elimination half-life, AUC0→t is the area under 
the plasma concentration-time curve from time zero to the last sampling time and AUC0→∞ is the area under the plasma concentration-time curve 
from time zero to infinity. 
 
RESULTS AND DISCUSSION 
Optimization of LC-ESI-MS/MS conditions 
Separation of these drugs on aquasil-C18 was examined using 
various combinations of acetonitrile and water mobile phase 
compositions with different percentage of modifiers. The 
combination of acetonitrile (A) and water containing 0.04 % glacial 
acetic acid (B) (80:20, v/v) was gave good separation for all the 
analytes with good peak shapes. The standard solutions at 10 µg/mL 
respective ATV, OLM and LOS were directly infused into the ESI 
mass spectrometer. The analytes ATV, OLM and LOS observed as 
prominent protonated molecular ions [M+H]+ in positive ion mode 
and showed the ions at m/z 559, 559 and 423 respectively. The 
[M+H]+ ions of respective analytes were subjected to collision 
induced dissociation (CID) for MS2
Method validation 
experiment at average collision 
energy of 30%. Later the collision energies were optimized for each 
analyte to obtain the intense fragment ions. The molecules 
undergone fragmentation and yield the following fragment ions at 
m/z 440, 541 and 405 for ATV, OLM and LOS respectively. The 
structures of these drugs and their putative fragments were also 
confirmed through exactive orbitrap high resolution mass 
spectrometer (Thermo Scientific, CA, USA).  
The specificity of this method was confirmed by comparing 
chromatograms of blank plasma, spiked plasma with analytes at a 
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concentration of 1ng/mL and plasma sample obtained after 1 h of 
oral administration shown in Fig. 2. ATV, OLM and LOS (IS) in LC-ESI 
experiment were well separated under the described 
chromatographic conditions and not observed any endogenous 
matrix interfering peaks around their retention times.  
The calibration curves of the analytes showed good linearity over 
the studied concentration range of 1-1000ng/mL for ATV and OLM 
with correlation coefficients (r2
Intra-day and inter-day accuracy of the method was found to be 90-
103 % for atorvastatin and 90 - 105 % for olmesartan respectively 
with the precision values was less than 10 % in terms of % RSD. The 
mean percentage recoveries of ATV and OLM were 70 to 96 % and 
74 to 95 % respectively. The results indicate the sample preparation 
technique is suitable for extracting the studied drugs from rat 
plasma. The stability studies of these drugs were performed at three 
QC concentration (low, medium and high) levels in six replicates 
(n=6). The predicted concentrations for each analyte deviated 
within ±10 % of nominal concentrations after storage of plasma 
samples at room temperature for 24 h, three freeze-thaw cycles and 
in auto sampler for 12 h at 4
) were 0.9998 and 0.9997 
respectively. The LODs and the LOQs were 0.15ng/mL and 1.0ng/mL 
for ATR and 0.21ng/mL and 1.0ng/mL for OLM respectively. 
o
Stability of both the drugs was performed for three QC 
concentrations. The recoveries of atorvastatin and olmesartan in all 
stability studies were found to be more than 90 % with less than 5 % 
precision (% RSD).  
C. The mean accuracies were found to 
be more than 90 % with relative standard deviations less than 10 %.  
System suitability parameters such as retention time, tailing factor 
and theoretical plates were taken into consideration. The system 
suitability was done by six replicate concentrations of 500ng/mL for 
atorvastatin and olmesartan. The acceptance criterion was ±2% for 
the percent relative standard deviation (%RSD) for peak area 
retention time for both the drugs. The % RSD of peak area and 
retention time for both the drugs were within 2% indicating the 
suitability of system. The efficiency of the column was determined 
by considering parameters like tailing factor and theoretical plates. 
All the values for the system suitability parameters were within 
acceptable range.  
 
 
Fig. 2: LC-ESI-MS/MS extracted ion chromatograms of (A) blank 
plasma, (B) spiked plasma at 1 ng/mL, and (C) plasma extracted 
from rats after 1 h of oral administration. 
Application to the pharmacokinetic study 
The established method was applied to analysis of plasma samples 
after an oral administration of 1mg kg-1and 2mg kg-1 of atorvastatin 
and olmesartan simultaneously in rats. The concentrations and 
mean plasma concentration - time profile of atorvastatin and 
olmesartan are shown in Fig.3. A non-compartmental model was 
used to estimate the pharmacokinetic parameters of atorvastatin 
and olmesartan in rat plasma. After administration of the three 
drugs, peak plasma concentrations (Cmax) were reached at 0.90 ± 
0.22 h and 0.70 ± 0.27 h (Tmax) with an elimination half-life (t1/2
 
) of 
3.89 ± 0.40 h and 3.56 ± 0.45 h for atorvastatin and olmesartan 
respectively. Thus the developed method was successfully applied 
for pharmacokinetic study in rats after administration of 




Fig. 3: Mean plasma concentration-time profile of atorvastatin 
and olmesartan in rat plasma after oral administration. Each 
point represents the mean ± SD (n = 6). 
 
CONCLUSION 
A simple and reliable LC-ESI-MS/MS assay was developed for 
quantitative evaluation of ATV and OLM simultaneously in rat plasma. 
Single step protein precipitation was used to extract analytes from rat 
plasma. The major advantages of the assay are simple sample 
preparation and short run time. The obtained LODs and LOQs of the 
drugs were adequate to perform the pharmacokinetic study in rat 
plasma. Based on the results we can conclude that the present method is 
not only suitable for assessing the pharmacokinetics but also applicable 
for clinical pharmacokinetics. 
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